PTCT
PTCT
NASDAQ · Biotechnology

Ptc Therapeutics Inc

$64.54
-1.88 (-2.83%)
As of Mar 24, 9:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
875.68M
Net Income
-394,318,222
Gross Margin
92.9%
Profit Margin
-45.0%
Rev Growth
+14.4%
D/E Ratio
848.93
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 92.9% 92.9% 60.4% 60.4%
Operating Margin -25.1% -22.6% 19.1% 18.3%
Profit Margin -45.0% -42.8% 16.6% 18.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 875.68M 765.32M 623.61M 650.14M
Gross Profit 813.42M 710.91M 376.75M 392.78M
Operating Income -219,970,995 -173,023,855 119.04M 119.01M
Net Income -394,318,222 -310,161,160 103.27M 119.61M
Gross Margin 92.9% 92.9% 60.4% 60.4%
Operating Margin -25.1% -22.6% 19.1% 18.3%
Profit Margin -45.0% -42.8% 16.6% 18.4%
Rev Growth +14.4% +14.4% +11.8% -7.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.79B 2.79B 693.46M 831.94M
Total Equity 3.28M 3.28M 3.87B 4.02B
D/E Ratio 848.93 848.93 0.18 0.21
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -145,212,798 -120,566,472 195.81M 183.50M
Free Cash Flow 61.49M 67.39M